Current pharmacotherapeutic options for treating deep vein thrombosis

Area of Science:

• Medical Science
• Pharmacology
• Vascular Medicine

Background:

• Deep vein thrombosis (DVT) management has undergone significant evolution over five decades.
• Initial treatments included subcutaneous unfractionated heparin (UFH) and warfarin, which became standard care.
• Recent advancements include low molecular weight heparins (LMWH) and thrombolytic agents.

Purpose of the Study:

• To review the historical and current management strategies for deep vein thrombosis (DVT).
• To highlight the advancements in anticoagulant and thrombolytic therapies for DVT.
• To provide a comprehensive overview of DVT treatment from acute to long-term care.

Main Methods:

• Literature review of studies on DVT treatment over the past 50 years.
• Analysis of the efficacy and administration of unfractionated heparin (UFH), warfarin, and low molecular weight heparin (LMWH).
• Examination of studies involving thrombolytic agents for DVT outcome improvement.

Main Results:

• Low molecular weight heparins (LMWH) demonstrate comparable or superior efficacy to UFH in acute DVT treatment.
• LMWH offers advantages such as subcutaneous administration, better absorption, and no requirement for monitoring.
• Thrombolytic agents aim to reduce clot burden and prevent long-term complications of DVT.

Conclusions:

• LMWH represents a significant paradigm shift in DVT patient care.
• The review encompasses the progression of DVT management, including acute and long-term phases.
• Current therapeutic approaches focus on optimizing outcomes and preventing sequelae of DVT.